(NASDAQ: KROS) Keros Therapeutics's forecast annual revenue growth rate of 624.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Keros Therapeutics's revenue in 2024 is $271,000.On average, 5 Wall Street analysts forecast KROS's revenue for 2024 to be $229,485,145, with the lowest KROS revenue forecast at $3,752,210, and the highest KROS revenue forecast at $1,130,165,562. On average, 1 Wall Street analysts forecast KROS's revenue for 2025 to be $2,345,881,504, with the lowest KROS revenue forecast at $2,345,881,504, and the highest KROS revenue forecast at $2,345,881,504.
In 2026, KROS is forecast to generate $3,812,845,409 in revenue, with the lowest revenue forecast at $2,585,272,483 and the highest revenue forecast at $4,951,040,699.